Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Phosphoric Acid. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102766092A details a mild chiral spiro phosphoric acid catalyzed synthesis of optically active tetrahydroquinolines, offering high enantioselectivity and simplified purification for API manufacturing.
Patent CN111848322B details a chiral phosphoric acid catalyzed resolution method yielding high-purity axially chiral oxindole-substituted styrenes for asymmetric catalysis applications.
Novel chiral phosphoric acid catalyzed resolution method for axially chiral oxindole-substituted styrenes. High ee values up to 96%. Ideal for pharma intermediates.
Novel synthesis of axial chiral cyclopentenyl indole-naphthyl compounds via chiral phosphoric acid. High enantioselectivity and cytotoxic activity for pharmaceutical applications.
Novel axial chiral bisindole catalysts for asymmetric synthesis. Superior stereoselectivity and mild conditions for pharmaceutical intermediates manufacturing.
Patent CN113735867B introduces mild room temperature synthesis of chiral indolo-oxa compounds with high yield and enantioselectivity offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing
Novel chiral indolinopyrrole synthesis via phosphoric acid catalysis achieves high enantioselectivity and scalability, enabling cost-effective API intermediate production for oncology therapeutics.
Breakthrough chiral phosphoric acid catalyst with spiro-bis-dihydrobenzothiole skeleton enables high-enantioselectivity asymmetric synthesis for pharmaceutical intermediates, offering reliable supply chain and cost reduction.
Novel chiral phosphoric acid-catalyzed synthesis achieves high enantioselectivity and yield for N-N axis pyrrole derivatives, enabling cost-effective pharmaceutical production with enhanced supply chain reliability.
Patent CN114478245A enables high-purity chiral intermediates with streamlined manufacturing and enhanced supply chain resilience for pharmaceutical applications.
Patent CN119060057B introduces a mild chiral phosphoric acid-catalyzed synthesis of indolocyclopentanes with high yield and selectivity, enabling scalable production and significant cost savings for pharmaceutical intermediates.
Breakthrough chiral indoxazinone synthesis with high enantioselectivity enables cost-effective manufacturing and reliable supply chain for oncology drug development.
Innovative chiral phosphoric acid catalyzed process delivers high enantioselectivity and yield for pharmaceutical intermediates ensuring scalable cost-effective production with stringent purity standards
Novel chiral pyrrole synthesis method enables high-yield production with exceptional enantioselectivity, enhancing pharmaceutical supply chain reliability and cost efficiency.
Patent CN116199614B enables high-yield synthesis of chiral catalysts with up to 98% ee, offering cost-effective and scalable production for pharmaceutical intermediates.
Patent CN119060057B introduces a mild chiral phosphoric acid catalyzed route achieving high stereoselectivity and yield for indolocyclopentanes compounds with significant cost reduction potential in pharmaceutical manufacturing.
Novel chiral phosphoric acid-catalyzed method enables high-yield enantioselective production with significant cost reduction and supply chain reliability for pharma intermediates.
Patent CN105017238B enables metal-free synthesis of optically active benzoxazinones with high ee values, offering cost reduction and reliable supply for pharmaceutical intermediates.
Patent CN115385916B enables high-yield chiral indolinopyrrole synthesis with exceptional enantioselectivity under mild conditions, delivering scalable pharmaceutical intermediates with reduced operational complexity.
Patent CN118878543A enables high-yield synthesis of chiral compounds with exceptional enantioselectivity exceeding 99% ee under mild conditions driving cost reduction in pharmaceutical manufacturing while ensuring supply chain reliability.